Artivion
Manufacturing · Georgia, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1655 Roberts Blvd NW, Kennesaw, Georgia,...Phone Number
(770) 419-3355Website
www.artivion.comRevenue
$458.7 MillionStock Symbol
AORTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Artivion
Artivion is a global medical technology company specializing in innovative solutions for the treatment of aortic disease. The company develops, manufactures, and distributes cardiac and vascular devices, implantable tissues, heart valves, surgical sealants, and stent grafts, partnering with surgeons worldwide to improve patient outcomes through advanced, high-quality technologies.Explore more
Artivion Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Artivion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Artivion has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Artivion recently announced quarterly report
Product Launch: Get notified when Artivion launches new products
Funding: Get notified immidiatlly once Artivion has new funding data
Congratulate Masked Content for being promoted to Masked Content at Artivion
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Artivion had a recent Job posting/layoffs
Check out if Artivion is spiking on competitors!
Artivion, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Artivion
Compare insights from companies similar to Artivion, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Artivion is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Artivion is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Artivion.
Artivion Tech Stack
A closer look at the technologies used by Artivion
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Artivion is planning to move offices in January 2027. The move will impact approximately 60 employees at the existing office located at 1300 E Anderson Ln, Austin, TX.
Facilities Relocation/Expansion
Earnings
Earnings, Finance
Pain Point
Artivion has reported that, for the first time in Q1, a number of surgeons began deferring AMDS adoption asking to be contacted after PMA approval rather than proceeding under the current HDE pathway representing a new headwind to near-term account conversions not previously encountered in the commercial launch.
CRM, Account Management
Project
Artivion has announced that its NEXUS aortic arch stent graft system, which holds full PMA approval with no HDE restrictions, will be launched without an upfront inventory purchase requirement, and surgeons will have the ability to perform cases on a one-off basis prior to full value analysis committee approval, differentiating the NEXUS commercial launch from the company's prior AMDS launch experience.
Medical Research
Pain Point
Pain Point, Sales
Artivion News & Media
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the...Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid...Artivion to Participate in the 2026 Truist Securities MedTech Conference
ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026, at the Boston Harbor...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Artivion
Sign Up For FreeTo access detailed company insights
Artivion is a global medical technology company specializing in innovative solutions for the treatment of aortic disease. The company develops, manufactures, and distributes cardiac and vascular devices, implantable tissues, heart valves, surgical sealants, and stent grafts, partnering with surgeons worldwide to improve patient outcomes through adv... Read More
